Qol Holdings Co. Achieves Record-High Sales and Profit in Q2 FY2026
Qol Holdings Co. reported record-high sales and profit for Q2 FY2026, driven by its acquisition of a larger stake in DAIICHI SANKYO ESPHA CO., LTD. and increased use of generic drugs. The pharmacy, BPO contracting, and pharmaceutical manufacturing sectors all experienced growth, aided by new product launches and higher demand for contract medical representatives. The company has a strong presence in the Japanese pharmaceutical market, with a current market cap of Yen72.3B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Qol Holdings Co ( (JP:3034) ) has provided an announcement.
Qol Holdings Co. reported record-high sales and profit for the second quarter of the fiscal year ending March 31, 2026. The company’s acquisition of a larger stake in DAIICHI SANKYO ESPHA CO., LTD. and increased use of generic drugs contributed to its financial success. The pharmacy business, BPO contracting, and pharmaceutical manufacturing sectors all showed higher sales and profit, with significant contributions from new product launches and increased demand for contract medical representatives.
More about Qol Holdings Co
Qol Holdings Co. operates in the pharmaceutical industry, focusing on pharmaceutical manufacturing, pharmacy business, and BPO contracting services. The company has a strong market presence, particularly in the Japanese market, and has recently increased its stake in DAIICHI SANKYO ESPHA CO., LTD., enhancing its influence in the pharmaceutical sector.
Average Trading Volume: 128,736
Current Market Cap: Yen72.3B
For an in-depth examination of 3034 stock, go to TipRanks’ Overview page.
